Table 1.
CPE and Claudin-4 mutations affecting the interaction between them.
| (A) CPE mutations affecting activity | ||||
|---|---|---|---|---|
| Mutation | Methods used | Approx. Cytotoxicity as % wild-type activity | Comment | Ref. |
|
| ||||
| Wild-type | 100 | - | ||
|
| ||||
| Full-length CPE | ||||
|
| ||||
| Asp48Ala/As n/Glu |
86Rb release | <1 | 30 | |
| Ile51Ala | 86Rb release | <1 | 30 | |
| Tyr306Ala | LDH release competition/TEER | 64/64 | 28 | |
| Tyr310Ala | LDH release competition/TEER | 72/94 | 28 | |
| Tyr312Ala | LDH release competition/TEER | 73/100 | 28 | |
| Leu315Ala | LDH release competition/TEER | 70/45 | 28 | |
|
| ||||
| C-terminal domain only | Claudin-4 binding as % wild-type | |||
|
| ||||
| Leu223Ala | Pull-down | 100 | Claudin-3 binding 20% | 34 |
| Arg227Ala | Pull-down | 80 | Claudin-3 binding 10% | 34 |
| Leu254Ala | Pull-down | 80 | Claudin-3 binding 30% | 34 |
| Asp284Ala | Pull-down | 10 | Claudin-3 binding 100% | 34 |
| (B) Claudin extracellular loop 2 mutations affecting C-CPE binding -numbering as for Claudin-2 ECL2 | ||||
| Mutation | Methods used | Approx. Binding as % wild-type activity | Comment | Ref. |
|
| ||||
| Wild-type | 100 | - | ||
|
| ||||
| Claudin 3 | ||||
|
| ||||
| Asn149Asp | Pull-down | 5 | Mouse ECL-2 peptide | 25 |
| Leu151Ala | Pull-down | 5 | Mouse ECL-2 peptide | 25 |
| Asn149Asp/Ar g158Tyr |
125I-CPE binding/TTC cytotoxicity |
1 | Human full-length | 39 |
| Asn149Asp | Pull-down | 50% | Mouse full-length | 34 |
|
| ||||
| Claudin 4 | ||||
|
| ||||
| Asn149Asp | Cytotoxicity | <1 | Human full-length | 40 |